1 Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez
J. Expression of protein tyrosine kinases in head and neck
squamous cell carcinomas. Am J Clin Pathol. 2005;124:71-6.
DOI: 10.1309/BTLN5WTMJ3PCNRRC, PMID: 15923166
2 Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang
H, Liu DD, et al. Epidermal growth factor receptor copy
number alterations correlate with poor clinical outcome in
patients with head and neck squamous cancer. J Clin Oncol.
2007;25:2164-70. DOI: 10.1200/JCO.2006.06.6605, PMID:
17538160
3 Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu
D, Au HJ, et al. Cetuximab for the treatment of colorectal
cancer. N Engl J Med. 2007;357:2040-8. DOI: 10.1056/
NEJMoa071834, PMID: 18003960
4 Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni
PJ. Correlation between development of rash and efficacy in
patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Clin Cancer Res. 2007;13:3913-21. DOI: 10.1158/1078-0432.
CCR-06-2610, PMID: 17606725
5 Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C,
Viganò MG, et al. Clinical Significance of Skin Toxicity due
to EGFR-Targeted Therapies. J Oncol. 2009;2009:1-8. DOI:
10.1155/2009/849051, PMID: 19584908
6 Bonomo P, Loi M, Desideri I, Olmetto E, Delli Paoli C,
Terziani F, et al. Incidence of skin toxicity in squamous cell
carcinoma of the head and neck treated with radiotherapy and
cetuximab: A systematic review. Crit Rev Oncol Hematol.
2017;120:98-110. DOI: 10.1016/j.critrevonc.2017.10.011,
PMID: 29198343
7 Petrelli F, Borgonovo K, Barni S. The predictive role of skin
rash with cetuximab and panitumumab in colorectal cancer
patients: a systematic review and meta-analysis of published
trials. Target Oncol. 2013;8:173-81. DOI: 10.1007/s11523-0130257-x, PMID: 23321777
8 Su X, Lacouture ME, Jia Y, Wu S. Risk of high-grade
skin rash in cancer patients treated with cetuximab--an
antibody against epidermal growth factor receptor: systemic
review and meta-analysis. Oncology. 2009;77:124-33. DOI:
10.1159/000229752, PMID: 19622903
9 Lacouture ME. Mechanisms of cutaneous toxicities to EGFR
inhibitors. Nat Rev Cancer. 2006;6:803-12. DOI: 10.1038/
nrc1970, PMID: 16990857
10 Solomon BM, Jatoi A. Rash from EGFR inhibitors: opportunities and challenges for palliation. Curr Oncol Rep.
2008;10:304-8. DOI: 10.1007/s11912-008-0048-1, PMID:
18778556
11 Wagner LI, Lacouture ME. Dermatologic toxicities associated
with EGFR inhibitors: the clinical psychologist’s perspective.
Impact on health-related quality of life and implications for
clinical management of psychological sequelae. Oncology
(Williston Park). 2007;21(suppl 5):34-6. PMID: 18154217
12 Rothschild SI, Betticher D, Zenhäusern R, Anchisi S,
von Moos R, Pless M, et al. Prospective, observational
practice survey of applied skin care and management of
cetuximab-related skin reactions: PROSKIN study. Cancer
Chemother Pharmacol. 2019;84:881-9. DOI: 10.1007/s00280019-03927-x, PMID: 31444619
13 Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien
CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med.
2009;360:1408-17. DOI: 10.1056/NEJMoa0805019, PMID:
19339720
14 Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A,
Rottey S, et al. Platinum-based chemotherapy plus cetuximab
in head and neck cancer. N Engl J Med. 2008;359:1116-27.
DOI: 10.1056/NEJMoa0802656, PMID: 18784101
15 Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan
A, Epstein JB, et al.; MASCC Skin Toxicity Study Group.
Clinical practice guidelines for the prevention and treatment
of EGFR inhibitor-associated dermatologic toxicities. Support
Care Cancer. 2011;19:1079-95. DOI: 10.1007/s00520-0111197-6, PMID: 21630130
16 Li T, Perez-Soler R. Skin toxicities associated with epidermal
growth factor receptor inhibitors. Target Oncol. 2009;4:10719. DOI: 10.1007/s11523-009-0114-0, PMID: 19452131
17 Uozumi S, Enokida T, Suzuki S, Nishizawa A, Kamata H,
Okano T, et al. Predictive Value of Cetuximab-Induced Skin
Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK. Front Oncol. 2018;8:616. DOI:
10.3389/fonc.2018.00616, PMID: 30619755
18 Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/
EGFR-targeted agents: is there a silver lining? J Clin Oncol.
2005;23:5235-46. DOI: 10.1200/JCO.2005.00.6916, PMID:
16051966
19 Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic antifungals in the treatment of chronic
paronychia: an open, randomized double-blind and double
dummy study. J Am Acad Dermatol. 2002;47:73-6. DOI:
10.1067/mjd.2002.122191, PMID: 12077585
20 Wollina U. Acute paronychia: comparative treatment with
topical antibiotic alone or in combination with corticosteroid.
J Eur Acad Dermatol Venereol. 2001;15:82-4. DOI: 10.1046/
j.1468-3083.2001.00177-6.x, PMID: 11451337
21 Rigopoulos D, Gregoriou S, Belyayeva E, Larios G,
Kontochristopoulos G, Katsambas A. Efficacy and safety of
tacrolimus ointment 0·1% vs. betamethasone 17-valerate 0·1%
in the treatment of chronic paronychia: an unblinded randomized study. Br J Dermatol. 2009;160:858-60. DOI: 10.1111/
j.1365-2133.2008.08988.x, PMID: 19120329
22 Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME,
McClure JS, et al. NCCN Task Force Report: management
of dermatologic and other toxicities associated with EGFR
inhibition in patients with cancer. J Natl Compr Canc Netw.
2009;7(Suppl_1):S-5-21. DOI: 10.6004/jnccn.2009.0074
23 Aygenc E, Celikkanat S, Kaymakci M, Aksaray F, Ozdem
C. Prophylactic effect of pentoxifylline on radiotherapy
complications: a clinical study. Otolaryngol Head Neck Surg.
2004;130:351-6. DOI: 10.1016/j.otohns.2003.08.015, PMID:
15054378
24 Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW.
Cutaneous side effects of epidermal growth factor receptor
inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317-26. DOI: 10.1016/
j.jaad.2006.09.005, PMID: 17141360
25 Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann
MH, et al. Practical management of patients with nonsmall-cell lung cancer treated with gefitinib. J Clin Oncol.
2005;23:165-74. DOI: 10.1200/JCO.2005.04.057, PMID:
15557594
383
© 2020 Tottori University Medical Press
K. Taira et al.
26 Watanabe S, Nakamura M, Takahashi H, Hara M, Ijichi K,
Kawakita D, et al. Dermopathy associated with cetuximab
and panitumumab: investigation of the usefulness of moisturizers in its management. Clin Cosmet Investig Dermatol.
2017;10:353-61. DOI: 10.2147/CCID.S140796, PMID:
28932126
27 Andoh T, Al-Akeel A, Tsujii K, Nojima H, Kuraishi Y.
Repeated treatment with the traditional medicine Unsei-in inhibits substance P-induced itch-associated responses through
downregulation of the expression of nitric oxide synthase
1 in mice. J Pharmacol Sci. 2004;94:207-10. DOI: 10.1254/
jphs.94.207, PMID: 14978361
28 Gao XK, Fuseda K, Shibata T, Tanaka H, Inagaki N, Nagai H.
Kampo Medicines for Mite Antigen-Induced Allergic Dermatitis in NC/Nga Mice. Evid Based Complement Alternat Med.
2005;2:191-9. DOI: 10.1093/ecam/neh077, PMID: 15937560
29 Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting
the epidermal growth factor receptor in cancer: apoptosis
takes center stage. Cancer Res. 2003;63:1-5. PMID: 12517767
30 Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T,
Kabashima K. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis.
Immunol Rev. 2017;278:246-62. DOI: 10.1111/imr.12545,
PMID: 28658541
31 Kamide D, Yamashita T, Araki K, Tomifuji M, Shiotani A.
Hangeshashinto (TJ-14) prevents radiation-induced mucositis
by suppressing cyclooxygenase-2 expression and chemotaxis
of inflammatory cells. Clin Transl Oncol. 2017;19:1329-36.
DOI: 10.1007/s12094-017-1672-8, PMID: 28516399
32 Ara T, Honjo K, Fujinami Y, Hattori T, Imamura Y, Wang PL.
Preventive effects of a kampo medicine, orento on inflammatory responses in lipopolysaccharide treated human gingival
fibroblasts. Biol Pharm Bull. 2010;33:611-6. DOI: 10.1248/
bpb.33.611, PMID: 20410594
33 Han C, Guo J. Antibacterial and anti-inflammatory activity of
traditional Chinese herb pairs, Angelica sinensis and Sophora
flavescens. Inflammation. 2012;35:913-9. DOI: 10.1007/
s10753-011-9393-6, PMID: 21976127
34 Kono T, Kaneko A, Matsumoto C, Miyagi C, Ohbuchi K,
Mizuhara Y, et al. Multitargeted effects of hangeshashinto
for treatment of chemotherapy-induced oral mucositis
on inducible prostaglandin E2 production in human oral
keratinocytes. Integr Cancer Ther. 2014;13:435-45. DOI:
10.1177/1534735413520035, PMID: 24501112
35 Chi YS, Kim HP. Suppression of cyclooxygenase-2 expression of skin fibroblasts by wogonin, a plant flavone from
Scutellaria radix. Prostaglandins Leukot Essent Fatty Acids.
2005;72:59-66. DOI: 10.1016/j.plefa.2004.04.009, PMID:
15589400
36 Samosor n S, Tanwirat B, Muhamad N, Casadei G,
Tomkiewicz D, Lewis K, et al. Antibacterial activity of
berberine-NorA pump inhibitor hybrids with a methylene
ether linking group. Bioorg Med Chem. 2009;17:3866-72.
DOI: 10.1016/j.bmc.2009.04.028, PMID: 19419877
37 Rohrer U, Kunz EM, Lenkeit K, Schaffner W, Meyer J.
Antimicrobial activity of Mahonia aquifolium and two of its
alkaloids against oral bacteria. Schweiz Monatsschr Zahnmed. 2007;117:1126-31. PMID: 18072463
384
© 2020 Tottori University Medical Press
...
論文の公開元へ
